Hyperbaric Oxygen for Adjuvant Therapy for Chronically Recurrent Mandibular Osteomyelitis in Childhood and Adolescence

Lentrodt, Stefan; Lentrodt, Jürgen; Kübler, Norbert; Mödder, Ulrich

doi:10.1016/j.joms.2005.11.106

« Previous Next »Journal of Oral and Maxillofacial Surgery
Volume 65, Issue 2 , Pages 186-191, February 2007

Hyperbaric Oxygen for Adjuvant Therapy for Chronically Recurrent Mandibular Osteomyelitis in Childhood and Adolescence

Stefan Lentrodt, MD
- Head, Hyperbaric Oxygen Unit, Institute of Diagnostic Radiology, Institute of Diagnostic Radiology and the Clinic of Maxillofacial Plastic Surgery, “Westdeutsche Kieferklinik,” University Hospital Düsseldorf, Düsseldorf, Germany.
- Address correspondence and reprint requests to Dr Lentrodt: Elbchaussee 185a, D-22605 Hamburg, Germany
Jürgen Lentrodt, MD, DDS
- Past Chairman, Clinic of Maxillofacial Plastic Surgery, “Westdeutsche Kieferklinik”, Institute of Diagnostic Radiology and the Clinic of Maxillofacial Plastic Surgery, “Westdeutsche Kieferklinik,” University Hospital Düsseldorf, Düsseldorf, Germany.
Norbert Kübler, MD, DDS
- Chairman, Clinic of Maxillofacial Plastic Surgery, “Westdeutsche Kieferklinik”, Institute of Diagnostic Radiology and the Clinic of Maxillofacial Plastic Surgery, “Westdeutsche Kieferklinik,” University Hospital Düsseldorf, Düsseldorf, Germany.
Ulrich Mödder, MD
- Chairman, Institute of Diagnostic Radiology, Institute of Diagnostic Radiology and the Clinic of Maxillofacial Plastic Surgery, “Westdeutsche Kieferklinik,” University Hospital Düsseldorf, Düsseldorf, Germany.

Purpose

In this article, the question of whether adjuvant hyperbaric oxygen therapy (HBO) has a positive effect when treating chronically recurrent mandibular osteomyelitis in children and adolescents is discussed.

Patients and Methods

Over a period of 5 years, 4 cases were observed, 3 of which were submitted to adjuvant HBO. Details on the modalities of this type of treatment and the simultaneous intravenous administration of high doses of antibiotics are reported.

Results

All 3 patients have been free of any symptoms from 20 to 74 months (mean, 41 months) and therefore may most likely be regarded as healed.

Conclusion

The small number of cases does not allow a final statement on the extent to which HBO contributed to the positive outcome. However, in our opinion, HBO is a most promising therapeutic option. Finally, the problems involved in prospective randomized studies of this rare disease are discussed in detail.